heart failure — LLMpedia

heart failure
Name	Heart failure
Field	Cardiology
Symptoms	Shortness of breath, fatigue, edema
Complications	Arrhythmia, pulmonary edema, renal dysfunction
Onset	Acute or chronic
Causes	Ischemic heart disease, hypertension, cardiomyopathy
Risks	Coronary artery disease, diabetes mellitus, obesity
Diagnosis	Echocardiography, BNP, ECG
Treatment	Pharmacotherapy, device therapy, transplant

Contents

heart failure Heart failure is a clinical syndrome characterized by the heart's inability to meet tissue metabolic demands, producing symptoms such as dyspnea and fluid retention. It is managed across settings including hospitals, clinics, and community services, and involves multidisciplinary teams from institutions such as Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, and Mount Sinai Hospital. Major guideline-producing bodies like the American Heart Association, European Society of Cardiology, National Institute for Health and Care Excellence, World Health Organization, and American College of Cardiology shape standards of care.

Signs and symptoms

Patients commonly present with exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea, fatigue, and peripheral edema, often prompting evaluation at centers such as St. Bartholomew's Hospital, Royal Brompton Hospital, Toronto General Hospital, Barnes-Jewish Hospital, and Karolinska University Hospital. Clinical examination may show elevated jugular venous pressure, pulmonary crackles, hepatomegaly, and S3 gallop, findings described in texts from Cleveland Clinic and research from Columbia University Irving Medical Center, University of Pennsylvania Health System, and University of California, San Francisco Medical Center. Decompensation can lead to pulmonary edema, cardiogenic shock, and multiorgan dysfunction recognized in case series from Bellevue Hospital, Mount Sinai Hospital, and King's College Hospital.

Etiologies include ischemic heart disease due to lesions documented by American College of Cardiology/American Heart Association registries and angiographic series from Mayo Clinic and Cleveland Clinic, hypertensive heart disease frequently reported in cohorts from Framingham Heart Study investigators, valvular diseases studied at Great Ormond Street Hospital, and primary cardiomyopathies described by researchers at Stanford University School of Medicine and University of Cambridge. Pathophysiology integrates neurohormonal activation (renin–angiotensin–aldosterone system, sympathetic overdrive) emphasized in trials from National Institutes of Health, myocardial remodeling noted in imaging studies at Johns Hopkins Hospital and Massachusetts General Hospital, and cellular mechanisms explored in laboratories at Harvard Medical School, University of Oxford, Yale School of Medicine, MIT, and University of Tokyo. Infectious causes feature studies from Centers for Disease Control and Prevention, while toxic and metabolic causes are reported by teams at University College London and Imperial College London.

Diagnostic strategies use biomarkers (B-type natriuretic peptide) and imaging (echocardiography, cardiac MRI) performed in facilities like Mayo Clinic, Johns Hopkins Hospital, Cleveland Clinic, Mount Sinai Hospital, and Royal Brompton Hospital. Electrocardiography, chest radiography, and invasive hemodynamic assessment in catheterization laboratories at Massachusetts General Hospital and University of Pennsylvania Health System complement noninvasive testing. Diagnostic criteria and staging appear in guidelines from European Society of Cardiology, American Heart Association, American College of Cardiology, National Institute for Health and Care Excellence, and position statements from the Heart Failure Society of America. Diagnostic research has been conducted by consortia at Framingham Heart Study, INTERMACS, Get With The Guidelines–Heart Failure, and cohorts from Duke University Medical Center.

Treatment includes guideline-directed medical therapy with agents validated in randomized trials from groups at Duke University, Yale School of Medicine, Stanford University School of Medicine, Brigham and Women's Hospital, and Vanderbilt University Medical Center. Pharmacologic classes include ACE inhibitors, ARBs, beta-blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors, and diuretics, with pivotal trials funded by entities such as the National Institutes of Health, pharmaceutical sponsors, and cooperative groups. Device therapies—implantable cardioverter-defibrillators, cardiac resynchronization therapy, and mechanical circulatory support—are offered at specialist centers including Cleveland Clinic, Mayo Clinic, Texas Heart Institute, and Johns Hopkins Hospital. Advanced therapies include heart transplantation performed at Cleveland Clinic, University of Maryland Medical Center, Cedars-Sinai Medical Center, and ventricular assist device programs endorsed by the United Network for Organ Sharing. Rehabilitation and palliative pathways are implemented in programs at Guy's and St Thomas' NHS Foundation Trust, Royal Melbourne Hospital, and community services linked to NHS England.

Prognosis varies by ejection fraction, comorbidity burden, and access to therapies; large registries from Framingham Heart Study, Get With The Guidelines–Heart Failure, INTERMACS, and national databases in United States and United Kingdom describe mortality, rehospitalization, and quality-of-life trajectories. Risk stratification tools developed at Cleveland Clinic, Mayo Clinic, and Duke University Medical Center inform clinical decision-making and transplant listing by organizations like United Network for Organ Sharing and Eurotransplant. Endpoints used in trials from European Society of Cardiology and American Heart Association include mortality, heart failure hospitalization, and patient-reported outcomes assessed in multicenter studies involving Columbia University Irving Medical Center and University of Washington Medical Center.

Prevalence and incidence estimates derive from population studies such as the Framingham Heart Study, Atherosclerosis Risk in Communities study, Cardiovascular Health Study, and national surveys conducted by the Centers for Disease Control and Prevention and Office for National Statistics. Major risk factors include coronary artery disease described in registries at American College of Cardiology, hypertension studied in cohorts by National Heart, Lung, and Blood Institute, diabetes mellitus characterized in studies from Joslin Diabetes Center, obesity research from Harvard T.H. Chan School of Public Health, smoking data from World Health Organization, and aging populations tracked by United Nations. Disparities in outcomes have been reported in analyses involving Robert Wood Johnson Foundation, Kaiser Permanente, Veterans Health Administration, and regional health systems in Australia, Canada, Germany, and Japan.